Thursday, November 4, 2021

Biolinq Adds $100M for Glucose Monitoring Sensors

San Diego-based Biolinq, a developer of continuous glucose monitoring sensors, said earlier this week that it has raised $100M in a Series B funding round. The funding was led by RiverVest Venture Partners, and also included T&W Medical, AXA IM Alts, Global Health Investment Corporation, Ascensia Diabetes Care, Longevity Vision Fund, Falcon Edge Capital, Aphelion Capital, M Ventures, Hikma Ventures, Senvest, The Broe Group, Taisho Pharmaceutical, Cirrus Logic, EOFlow, Able Partners and the JDRF T1D Fund. Biolinq is developing medical devices which incorporate a "microarray" of biosensors which measure the interstitial fluid glucose levels just under the surface of the skin, which are incorporated into a wearable device. The company's CEO is Rich Yang; the company's co-founders are Jared Tangney, PhD, and Joshua Windmiller, PhD. More information »